Premium
Fibroscan liver stiffness after anti‐viral treatment for hepatitis C is independently associated with adverse outcomes
Author(s) -
Vutien Philip,
Kim Nicole J.,
Moon Andrew M.,
Pearson Meredith,
Su Feng,
Berry Kristin,
Gelman Hannah,
Ioannou George N.
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16092
Subject(s) - medicine , cirrhosis , liver disease , hepatocellular carcinoma , gastroenterology , hepatitis c , decompensation , cohort , liver transplantation , hepatitis c virus , proportional hazards model , transplantation , immunology , virus
Summary Background Fibroscan‐derived liver stiffness decreases after anti‐viral treatment for hepatitis C virus (HCV) infection, which may affect the associations and interpretation of liver stiffness. Aims To assess whether liver stiffness pre‐ or post‐anti‐viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma (HCC) or death. Methods In this retrospective cohort study, we identified US veterans who initiated HCV treatment and had at least one liver stiffness before (n = 492) or after (n = 877) HCV therapy. We used Cox proportional hazards regression (adjusting for age, race/ethnicity, history of cirrhosis, body mass index, diabetes, FIB‐4 score, Charlson comorbidity index, alcohol use disorder, Model for end‐stage liver disease score and sustained virological response status) to determine the associations between pre‐ or post‐treatment liver stiffness values and the development of decompensated cirrhosis, HCC, death or liver transplant. Results In the post‐treatment liver stiffness cohort, during a mean follow‐up of 27.3 months, 21 (2.4%) developed decompensated cirrhosis, 26 (3.0%) developed HCC and 57 (6.5%) died or underwent liver transplant. Compared to patients with post‐treatment liver stiffness ≤12.5 kPa, those with post‐treatment liver stiffness >20 kPa, had higher rates of developing decompensated cirrhosis (adjusted HR 3.85, 95% CI 1.29‐11.50) and the composite outcome of death, liver transplant, decompensated cirrhosis or HCC (adjusted HR 1.95, 95% CI: 1.07‐3.56). There were no significant associations between pre‐treatment liver stiffness and any outcomes on multivariable analysis. Conclusions Post‐treatment liver stiffness >20 kPa, but not pre‐treatment liver stiffness, was independently associated with the development of decompensated cirrhosis and the composite outcome in multivariable analyses. Measuring liver stiffness should be considered after anti‐viral treatment because it predicts adverse outcomes even beyond routinely available clinical predictors.